Dr. Deepti Satelli, MD

Dr. Satelli practices at The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System.

Dr. Satelli's NPI, 1255561155, was assigned on July 26, 2009. Dr. Satelli holds Missouri license 2016014430.

Dr. Satelli's primary practice is The University of Kansas Hospital, at 4000 Cambridge Street, Kansas City, KS 66160 in Wyandotte County. The practice phone is (913) 588-5000.

Dr. Satelli's primary practice is The University of Kansas Hospital in Kansas City, Kansas, part of The University of Kansas Health System. Dr. Satelli is also affiliated with Saint Luke's North Hospital-Barry Road. The medical group on file is Kansas University Physicians. Dmand AI also links Dr. Satelli to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Satelli practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Satelli's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Satelli's licenses on file in 2 states: Missouri and Kansas.

CMS data shows 754 Medicare services from Dr. Satelli across 10 procedure codes in 2024, for 353 Medicare patients. Medicare paid $54,256 for them.

CMS counts 353 Medicare patients who saw Dr. Satelli in 2024. The largest group is 65 to 74, with 180 patients. 74% of them have high blood pressure, and 71% have cancer. 6% are also on Medicaid. Their average risk score is 1.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Satelli's median patient age at 71, with 88% women.

In 2024, Dr. Satelli wrote 1,725 Medicare Part D claims for 343 patients. 86% of them were for generic drugs. CMS names the drug for 1,453 of them, across 26 drugs with 11 or more claims each, at $1,465,120 in total drug cost. In 2023, CMS named 1,314 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Satelli for performance year 2024, reported through an alternative payment model (APM). Dr. Satelli accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Satelli as offering telehealth.

CMS Open Payments shows 12 general payments to Dr. Satelli from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 56% of the total. Daiichi Sankyo Inc. paid the most, $117.